1,5-二甲基-吡咯烷-3-醇 | 89584-08-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1,5-二甲基-吡咯烷-3-醇
• 英文名称: 3-Hydroxy-1,5-dimethyl-pyrrolidin
• 英文别名: 1,5-Dimethylpyrrolidin-3-OL
• CAS: 89584-08-7
• 化学式: C₆H₁₃NO
• 分子量: 115.175
• InChiKey: CIOLSWLKRIJZQO-UHFFFAOYSA-N

物化性质

• 沸点：
  70-80 °C(Press: 10 Torr)
• 密度：
  0.986±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,5-二甲基-吡咯烷-3-醇 在 盐酸 、 四氯化碳 、 sodium hydride 、 三苯基膦 作用下， 以 氯仿 、 二甲基亚砜 为溶剂， 生成 2-(2-chloropropyl)-2,3-dihydro-4-methylpyrido[3,2-f]-1,4-oxazepin-5(4H)-one
  参考文献：
  名称：

  Benzo- and pyrido-1,4-oxazepin-5-ones and -thiones: synthesis and structure-activity relationships of a new series of H1-antihistamines

  摘要：

  A series of novel benzo- and pyrido-1,4-oxazepinones and -thiones which represents a new structural class of compounds possessing H1 antihistaminic activity was synthesized, and the SARs were evaluated. The antihistaminic activity was determined by blockade of histamine-induced lethality in guinea pigs. The sedative potential was determined by comparison of the EEG profiles of the compounds with those of known sedating and nonsedating antihistamines. Several of the compounds were shown to possess potent H1 antihistaminic activity and to be free of the cortical slowing with synchronized waves and spindling activity found in the EEG of sedative antihistamines. One compound, 2-[2-(dimethylamino)ethyl]-3,4-dihydro-4-methylpyrido[3,2-f]-1,4- oxazepine-5(2H)-thione (rocastine) is currently undergoing clinical evaluation as a nonsedating H1 antihistamine.

  DOI：

  10.1021/jm00129a026

文献信息

• Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur
  申请人：A. H. Robins Company, Inc.

  公开号：US04705853A1

  公开（公告）日：1987-11-10

  Aromatic azepinones and thiones having the formula ##STR1## wherein; A is benzene, naphthalene, quinoline or pyridine; B is oxygen or sulfur; E is oxygen, sulfur or ##STR2## n is 1, 2 or 3; Z is an amino or a heterocyclic nitrogen-containing radical; R is hydrogen, loweralkyl, cycloalkyl or phenylloweralkyl; Y is halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, amino, loweracetylamino, trifluoromethyl, phenyl or phenyl substituted by one to three Y' radicals selected from halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, amino, loweracylamino or trifluoromethyl; and having antihistaminic utility, a process for the preparation thereof and chemical intermediates therefor are disclosed.

  芳香族氮杂七元酮和硫醚的化学式为##STR1##其中；A为苯、萘、喹啉或吡啶；B为氧或硫；E为氧、硫或##STR2##n为1、2或3；Z为氨基或含氮杂环的基团；R为氢、较低烷基、环烷基或苯基较低烷基；Y为卤素、较低烷基、较低烷氧基、二较低烷基氨基、硝基、氨基、较低乙酰氨基、三氟甲基、苯基或被从卤素、较低烷基、较低烷氧基、二较低烷基氨基、硝基、氨基、较低酰胺基或三氟甲基中选择的一个至三个Y'基团取代的苯基；具有抗组胺作用，公开了其制备方法和化学中间体。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110300104A1

  公开（公告）日：2011-12-08

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the Hepatitis C Virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the Hepatitis C Virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了具有式（I）的化合物，或其药学上可接受的盐、酯或前药：这些化合物抑制RNA含病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• Boronic ester and acid compounds, synthesis and uses
  申请人：Adams Julian

  公开号：US20070282100A1

  公开（公告）日：2007-12-06

  Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.

  本文揭示了一种减少动物蛋白质降解速率的方法，包括将动物细胞与某些硼酸酯和酸化合物接触。本文还揭示了新型硼酸酯和酸化合物，它们的合成和用途。
• COMPOUNDS
  申请人：ARÁNYI Péter

  公开号：US20110118305A1

  公开（公告）日：2011-05-19

  Heterocyclic amides useful as inhibitors of dipeptylpeptidase-IV (DPP-IV) enzyme, process for the preparation thereof and intermediates therefore.

  杂环酰胺可用作二肽基肽酶-IV（DPP-IV）酶抑制剂，其制备方法及中间体。
• Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
  申请人：Duggan Heather Mary Ellen

  公开号：US20110124638A1

  公开（公告）日：2011-05-26

  There is provided a compound of formula I: , or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供了一个公式I的化合物，或其药学上可接受的盐。还提供了制造公式1化合物的工艺，以及使用公式1化合物作为药物和治疗癌症的用途。